Overall rank by patents
#8,453
of 50,000 tracked assignees
USPTO PatentsView assignee record - 38 granted patents across 8 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).
The verdict
According to USPTO PatentsView, Novimmune ranks #8,453 of 50,000 tracked US assignees by granted-patent volume, with 38 patents across 8 technology areas.
USPTO PatentsView assignee plate
Corpus R8453 · Foreign Corporation #8,453 · 38 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL
Nearest grant-volume peer: National Chain Company (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Domo · near
32 score
Novimmune · this assignee
32 score
Portola Pharmaceutic… · near
32 score
SPD Swiss Precision… · near
32 score
STAT Medical Devices · near
32 score
3D Lighting Innovati… · lowest
7 score
What this shows Novimmune Sa stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-PAR, TYPE-FRNCORP, VEL-DOWN, BOOK-FULL. Volume places it #8,453 of 50,000; Innovation Score 32.3/100 sits in the top 59% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is National Chain Company (±0 grants).
Novimmune Sa has been granted 38 US utility patents between 2016 and 2023, placing Novimmune Sa at #8,453 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.4 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Novimmune Sa is one of the more focused assignees in the PatentsView dataset. By volume, Novimmune sits between Nidec Copal Electronics Corporation (38 patents, rank #8,449) and Parata Systems, Llc (38 patents, rank #8,457) - the closest US assignees by grant volume. The composite Innovation Score of 32.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 16 grants, compared with 22 in the 2015–2019 window, a -27% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Novimmune Sa's 11.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NIDEC COPAL ELECTRONICS CORPORATION
38 patents
NIPPON CHEMIPHAR CO., LTD.
38 patents
National Chain Company
38 patents
National Steel Car Limited
38 patents
ORMAT TECHNOLOGIES INC.
38 patents
OTOS WING CO., LTD.
38 patents
OsteoMed LLC
38 patents
PARATA SYSTEMS, LLC
38 patents
Novimmune SA
38 patents
What this shows Novimmune holds 38 patents at rank #8,453, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #8,453 in granted patent volume.
Other assignees with the most granted patents in Novimmune's primary technology class.
Two PlainPatent-derived peer sets for Novimmune, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (32 here).
Novimmune's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
32 Top 59% higher than 41% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 4 | 10.5% |
| 2017 | 10 | 26.3% |
| 2018 | 4 | 10.5% |
| 2019 | 4 | 10.5% |
| 2020 | 7 | 18.4% |
| 2021 | 3 | 7.9% |
| 2022 | 3 | 7.9% |
| 2023 | 3 | 7.9% |
Top 8 of 8 technology areas
Overall rank by patents
#8,453
of 50,000 tracked assignees
32.3 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.